Table 2.
Comparison between patients with spontaneous CBD stone passage and CBD stone non-passage in cholangitis.
| Characteristics | Spontaneous CBD stone passage (N = 19) | CBD stone non-passage (N = 77) | P value |
|---|---|---|---|
| Male (%) | 5 (26.3) | 34 (44.2) | 0.156 |
| Age (years; mean ± SD) | 56.6 ± 21.5 | 65.3 ± 17.1 | 0.085 |
| Blood test - Total bilirubin (mg/dL; mean ± SD) - Direct bilirubin (mg/dL; mean ± SD) - Aspartate transaminase (U/L; mean ± SD) - Alanine transaminase (U/L; mean ± SD) - Alkaline phosphatase (U/L; mean ± SD) |
5.10 ± 2.36 3.96 ± 1.99 227.6 ± 178.0 285.9 ± 353.4 291.1 ± 202.8 |
6.05 ± 6.05 4.63 ± 4.90 261.9 ± 325.4 221.1 ± 209.2 322.4 ± 235.1 |
0.550 0.451 0.511 0.556 0.613 |
| CBD dilate, diameter > 8 mm (%) | 13 (68.4) | 67 (87) | 0.051 |
| CBD stone diameter < 5 mm (%) | 15 (78.9) | 14 (18.2) | <0.001* |
| Single CBD stone (%) | 17 (89.5) | 37 (48.1) | 0.001* |
| Distal CBD stone (%) | 19 (100) | 68 (88.3) | 0.117 |
| Clinical symptoms improved before procedurea (%) | 18 (94.7) | 46 (59.7) | 0.004* |
| Time from hospital arrival to ERCP ≤ 48 h (%) | 11 (57.9) | 45 (58.4) | 0.965 |
| Post-ERCP complication (%) - Pancreatitis |
4 (21.1) 4 (21.1) |
8 (10.4) 5 (6.5) |
0.208 0.051 |
| Mortality (%) | 0 (0) | 2 (2.6) | 0.478 |
| Length of hospital stay (days; mean ± SD) | 6.8 ± 3.7 | 8.5 ± 5.8 | 0.311 |
*significant at the level of 0.05.
a
Clinical symptoms improve - no fever and abdominal pain.